Jonathan Schneck (Professor of Pathology, Medicine and Oncology) received his MD-PhD in Immunology from the Albert Einstein College of Medicine. After completing his degree, Dr. Schneck trained in Pediatrics at the Children’s Hospital National Medical Center in Washington DC. From there he went to the National Institute of Allergy and Immunology at the NIH in Bethesda and did his postdoctoral training at the Laboratory of Immunology. He joined the faculty at Johns Hopkins School of Medicine in 1990 and is currently a Professor in Pathology, Medicine and Oncology. He has received several awards including: the Mellon Clinician Scientist Award, Harry Weaver Neuroscience Scholar Award, RJR Research Scholars Award, Multiple Myeloma Research Foundation Scholar’s Award and recently was received a gift from the Susan Wojcicki and Denis Troper Charitable Foundation for his groundbreaking work in cancer immunology. He also recently became an associate editor at JCI, the Journal of Clinical Investigations.
Dr. Schneck’s research has focused on understanding and manipulating T cells responses and developing novel technology to address those questions. Notably, he developed, patented and licensed several products including the soluble multivalent MHC complex, MHC-Ig, sold by Becton Dickenson under the product name of DimerX, and artificial Antigen Presenting Cells, aAPC. Dr. Schneck is a co-founder and head of the SAB of NexImmune, http://www.neximmune.com, a biotech start-up company that has licensed the aAPC technology from JHMI. In addition, he is actively involved in teaching at JHMI and leads the Genes to Society Immunology course in the School of Medicine. Current projects in the lab relate to CD8 T cell function, multiscale analysis of immune responses and development of novel immunotherapy platform technologies.